依达拉奉联合神经节苷脂治疗大面积脑梗死的疗效分析

Edaravone and ganglioside GM - 1 for severe cerebral infarction.

目的 探讨依达拉奉联合治疗大面积脑梗死的实际疗效。方法 将发病48h内的大面积脑梗死的病人67例．随机分入治疗组和对照组。对照组应用依达拉奉注射剂30mg静脉滴注，每日2次，共21d，同时给予阿司匹林、低分子肝素作为基础治疗；治疗组除应用依达拉奉外尚应用神经节苷脂注射液20mg静脉滴注，每日一次，共21d。发病72h和治疗后定期对患者行欧洲卒中评分（ESS）、日常生活活动能力（ADL）评分，以治疗21dESS的评分和第90d的ADL评分作为主要疗效判断标准。结果 21d后联合治疗组和对照组的ESS评分分别为（68．12±17．58）、（51．29±15．36），两组相比差异有显著性（P〈0．01）；90d后治疗组、对照组ADL（改良Barthel指数）评分分别为（74．75±23．52）、（54．85±33，93），两组相比有差异有显著性（P〈0．01）。结论 依达拉奉联合神经节苷脂治疗大面积脑梗死疗效明显。

Objective To investigate the efficacy of edaravone and ganghoside GM - 1 for severe cerebral infarction. Methods 67 patients with severe cerebral infarction within 48 hours after the onset of stroke symptom were randomly assigned to receive edaravone and gangiioside GM - 1 （ n = 37 ） or edaravone （control group, n =30）. Edaravone and gangiioside GM - 1 were infused at a dose of 30 mg twice a day or 20mg per day, respectively, for 21 days. Meanwhile aspirin and low - molecular - weight heparin were used as basic treatment, 72h after onset and 21 day and 3 months after treatment, the neurological deficits were evaluated with the use of European Stroke Scale （ESS） and activities of daily living （ADL）. Results There were significant differences in ESS between GM - 1 group and control group at 21 day （68, 12± 17.58 vs. 51.29 ± 15.36, P 〈0.01 ）. There were also significant differences in ADL at 90 day between the groups （74.75 ±23.52 vs. 54.85 ± 33.93, P 〈 0.01 ）. Conclusion Edaravone and ganglioside GM - 1 has a good therapeutic effect for severe cerebral infarction.